Polyrizon Ltd. is a biotechnology company focused on developing innovative solutions for the medical and healthcare sectors, particularly in the realm of drug delivery and tissue protection. The company is at the forefront of creating unique polymer-based products designed to enhance the efficacy and safety of therapeutic applications. By leveraging advanced materials science, Polyrizon aims to address various clinical challenges, potentially improving patient outcomes through its proprietary technologies. Their research emphasizes enhancing the biocompatibility and performance of medical treatments, particularly in the fields of wound care, vaccination, and regenerative medicine. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Active Stocks Releasing News Recently to Watch Now: Myseum, Inc. (NASDAQ: MYSE ), SurgePays, Inc. (NASDAQ: SURG ), ENDRA Life Sciences (NASDAQ: NDRA ), Scienjoy Corp (NASDAQ: SJ ), Roadzen Inc (NASDAQ: RZDN ), Kartoon Studios, Inc (NYSE: TOON ), Power Metallic Mines (TSX-V: PNPN | OTCQB: PNPNF ), Synergy CHC Corp. (NASDAQ: SNYR ), Datavault AI (NASDAQ: DVLT ) and Peraso Inc (NASDAQ: PRSO ) — all active in trading sessions and should be added to your radar now as momentum accelerates across the small-cap biotech, tech, media and AI sectors.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to respiratory defense. Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotechnology company, aims to transform a bold lab-born vision into a scalable reality. With the recent announcement of a pivotal manufacturing milestone, Polyrizon is no longer just a promising startup—it is advancing its efforts to develop non-pharmacological solutions that could shield global populations from seasonal woes and beyond.
Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.
Ra’anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform. This achievement marks a critical step toward supporting upcoming clinical and regulatory activities, as well as potential commercial readiness in the future.
Ra’anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced encouraging results from a recent pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation. The study was designed to simulate allergen exposure conditions and assess the ability of PL-14 to prevent allergen penetration through a hydrogel barrier. In the pre-clinical study, Der p 1 allergen, a major house dust mite allergen, was applied atop the PL-14 formulation. Samples were collected beneath the formulation at multiple time points to measure the quantity and pace of allergen penetration.
Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, and regulatory pathways. This submission represents a significant progress in Polyrizon’s regulatory strategy, paving the way for potential marketing clearance and addressing a critical unmet need in allergy treatment.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
